Nobligan Retard (Tramadol Hydrochloride)

Tramadol works by binding to μ‑opioid receptors in the central nervous system, producing opioid‑like analgesia. At the same time, it blocks the reuptake of norepinephrine and serotonin, which enhances descending inhibitory pain pathways and further reduces the perception of pain.

The specific dose of Nobligan Retard is determined by the prescribing clinician based on the patient’s pain intensity, previous opioid exposure, and overall health status. Dosage may be adjusted during treatment, and the medication should be taken exactly as directed on the prescription label.

Safety data for tramadol in pregnancy and lactation are limited. Because potential risks to the fetus or infant cannot be ruled out, the product is generally avoided unless the expected benefit justifies the potential hazard. Healthcare providers should discuss individual risks with the patient.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide. After the request, the sales team will verify trade or institutional credentials, then provide pricing, availability, shipping details and any necessary import documentation.

Compared with stronger opioids such as morphine, tramadol offers a milder μ‑opioid receptor activation and adds serotonergic and noradrenergic activity, which can provide effective pain relief with a potentially lower risk of respiratory depression. However, it carries unique risks like serotonin syndrome and a lower seizure threshold, which differ from classic opioids.

Nobligan Retard tablets should be stored at ambient temperature, preferably below 25 °C. Keep them in the original container to protect from moisture and light. Do not crush or split the extended‑release tablets, as this can alter the release profile and increase the risk of adverse effects.

The medication is taken orally, whole, with a full glass of water. It should be swallowed without chewing, crushing, or breaking to maintain the extended‑release mechanism. Doses are usually spaced at regular intervals as prescribed, and the tablet should be taken at the same time each day for consistent pain control.

The most critical risks include respiratory depression, which can be life‑threatening, especially in opioid‑naïve or high‑risk patients; seizures, particularly at high doses or when combined with other seizure‑lowering agents; and serotonin syndrome when used with serotonergic drugs. Prompt medical attention is required if any of these symptoms appear.

Patients with a known hypersensitivity to tramadol or any component of the tablet should avoid it. It is also contraindicated in individuals taking monoamine oxidase inhibitors (MAOIs) or those with uncontrolled epilepsy, severe respiratory depression, or significant head injury. Clinicians must assess each patient’s medical history before prescribing.